September 28, 2016
1 min read
Save

Interleukin-6 monoclonal antibody at specific dosage improved response of patients with lupus

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

An interleukin-6 monoclonal antibody — as a 10 mg dose — improved the composite response of patients with lupus, according to recent phase 2 trial.

“Recently, a Pfizer anti-[interleukin-6] IL-6 (PF-04236921) demonstrated significant improvements in a composite response rate ([British Isles Lupus Assessment Group-based Composite Lupus Assessment] BICLA) and decreased flares in one of the three dosing groups,” Daniel J. Wallace, MD, associate director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, told Healio Rheumatology.

Daniel J. Wallace

Wallace and colleagues performed a study of 183 patients who received either placebo (n = 45) or PF-04236921 (Pfizer), an IL-6 monoclonal antibody against systemic lupus erythematosus (SLE), in doses of 10 mg (n = 45), 50 mg (n = 47) or 200 mg (n = 46) subcutaneously every 8 weeks. At week 24, the researchers assessed SLE Responder Index (SRI-4) and the BICLA.

The 200-mg dose was discontinued due to safety concerns and was not included in the efficacy analysis.

The SRI-4 did not significantly increase for any dose vs. placebo, except for the 10-mg group (59.9% vs. 40.1%). Severe flare incidence was significantly reduced when 10-mg and 50-mg groups were combined. In patients with increased disease activity at baseline, there was a significant increase in both SRI-4 (73.1% vs. 27.7%) and BICLA (55.7% vs. 19.7%) response rates for the 10-mg group. Three deaths occurred in the 200-mg group and one occurred in the 10-mg group. The most frequently reported adverse events were headache, nausea and diarrhea.

“In a phase 1 study conducted at the NIH, tociluzumab clearly had antiinflammatory actions in lupus patients,” Wallace said. He added, “Clearly, blocking IL-6 is worthy of further study in SLE.” – by Will Offit

Disclosures: Wallace reports he is a consultant for GlaxoSmithKline, Lilly, Merck Serono and UCB. Please see the full study for a list of all other researchers’ relevant financial disclosures.